Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rarely diagnosed fatal heart disease affecting an estimated 400,000 people globally, although the true prevalence is unknown and may be higher. , Bayer is committed to optimise the care for patients liv
Transthyretin amyloid cardiomyopathy can cause serious health issues over time. Here’s what might happen: Early stage. You may have mild symptoms or not realize you have a heart problem. Mid-stage. Symptoms like shortness of breath, swelling, and fatigue become more obvious. Advanced stage. ...
We are currently enrolling adults 18 to 90 years of age who have been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). If you are interested in taking part in this study, please continue below and complete the questionnaire to determine your eligibility. This is a depleter study,...
Transthyretin amyloid cardiomyopathy (ATTR-AC) is an under-recognized and underdiagnosed disease. Although traditionally considered a rare condition, the epidemiology of the disease is rapidly changing due to the possibility of non-invasive diagnosis through cardiac scintigraphy with bone tracers and novel...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of amyloidosis, which is a group of diseases where abnormal proteins (amyloids) build up and affect areas of the body. ATTR-CM is a long-term, progressive heart condition where the amyloids build up in the heart. This makes it harder...
Transthyretin amyloid cardiomyopathy ATTR is the result of TTR deposition, a tetrameric plasma protein whose function is to transport thyroxine and retinol-bound protein. TTR is mainly synthesized in the liver, although also to a lesser extent in other locations such as the choroid plexuses or the...
*Also known as transthyretin amyloid cardiomyopathy (ATTR-CM). Early, accurate diagnosis of ATTR cardiac amyloidosis can benefit patient care and may lead to improved outcomes.3,4 Learn more about what to look for to raise suspicion of ATTR cardiac amyloidosis and how to diagnose the disease....
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart failure caused by the buildup of abnormal proteins in the heart muscle. The protein...Become a member and unlock all Study Answers Start today. Try it now Create an account Ask a question Our experts can answer your tough...
Hereditary transthyretin amyloidosis (hATTR) is an autosomal dominant, adult-onset disease that stems from point mutations in the TTR gene encoding the protein transthyretin. The disease is progressive and life-threatening and is associated with amyloid deposits in multiple organs including ...
Transthyretin amyloid cardiomyopathy, an often unrecognized cause of heart failure, is now treatable with a transthyretin stabilizer. It is therefore important to identify at-risk patients who can undergo targeted testing for earlier diagnosis and treatment, prior to the development of irreversible heart...